A Potential Role of Ethosuximide and Pentoxifylline in Relieving Abdominal Pain in Irritable Bowel Syndrome Patients Treated with Mebeverine: A Randomized, Double-Blind, Placebo-Controlled Trial

Sahar M El-Haggar, Sahar K Hegazy, Sherief M Abd-Elsalam, Eslam B Elkaeed, Ahmed A Al-Karmalawy, Mostafa M Bahaa, Sahar M El-Haggar, Sahar K Hegazy, Sherief M Abd-Elsalam, Eslam B Elkaeed, Ahmed A Al-Karmalawy, Mostafa M Bahaa

Abstract

Background and purpose: Irritable bowel syndrome (IBS) is defined as an association of chronic abdominal pain with bowel habit abnormalities, without clear organic dysfunction. T-type calcium channels and low-grade mucosal inflammation are linked to abdominal pain; however, medical treatments for IBS abdominal pain are largely ineffective. In this study, we investigated if pentoxifylline (PTX) and ethosuximide could potentially alleviate abdominal pain in patients with IBS treated with mebeverine.

Methods: We recruited 150 patients from Tanta University Hospital to this randomized, prospective, and double blinded study. Patients were randomly allocated to three groups (n = 50). Group 1 (mebeverine) received 135 mg mebeverine three times/day (t.i.d). Group 2 (ethosuximide group) received 135 mg mebeverine t.i.d plus 250 mg ethosuximide twice daily (b.i.d) and group 3 (PTX group) received 135 mg mebeverine t.i.d plus 400 mg PTX b.i.d. Patients were assessed by a gastroenterologist at baseline and 6 months after therapy. Serum interleukin-8 (IL-8), IL-6, tumor necrosis-α (TNF-α), fecal myeloperoxidase, and fecal neutrophil gelatinase associated lipocalin (NGAL) levels were measured before and after therapy. The numeric pain rating scale (NRS) was also assessed before and after therapy.

Primary outcomes: Reduced NRS scores and abdominal pain relief.

Secondary outcomes: Decreased inflammatory biomarkers.

Results: After 6 months, groups 2 and 3 showed a significantly greater reduction in serum IL-8, IL-6, TNF-α, fecal myeloperoxidase, and fecal NGAL levels when compared to group 1 after therapy. Both groups 2 and 3 showed significant reductions in NRS scores when compared to the group 1.

Conclusion: Ethosuximide and PTX may be promising, novel adjunct drugs to antispasmodics for relieving abdominal pain in patients with IBS.

Trial registration: Identifier: NCT04217733.

Keywords: Ca++ channels; IBS; ethosuximide; inflammation; pentoxifylline.

Conflict of interest statement

The authors report no conflicts of interest in this work.

© 2022 El-Haggar et al.

Figures

Graphical abstract
Graphical abstract
Figure 1
Figure 1
CONSORT diagram showing the disposition of all patients screened for the study.

References

    1. Picard E, Carvalho FA, Agosti F, et al. Inhibition of Cav3. 2 calcium channels: a new target for colonic hypersensitivity associated with low‐grade inflammation. Br J Pharmacol. 2019;176(7):950–963. doi:10.1111/bph.14608
    1. Kerckhove N, Scanzi J, Pereira B, et al. Assessment of the effectiveness and safety of ethosuximide in the treatment of abdominal pain related to irritable bowel syndrome–IBSET: protocol of a randomised, parallel, controlled, double-blind and multicentre trial. BMJ Open. 2017;7(7):e015380. doi:10.1136/bmjopen-2016-015380
    1. Cervero F, Laird JM. Role of ion channels in mechanisms controlling gastrointestinal pain pathways. Curr Opin Pharmacol. 2003;3(6):608–612. doi:10.1016/j.coph.2003.06.007
    1. Wood JD. Neuropathy in the brain-in-the-gut. Eur J Gastroenterol Hepatol. 2000;12(6):597–600. doi:10.1097/00042737-200012060-00002
    1. Scanzi J, Accarie A, Muller E, et al. Colonic overexpression of the T‐type calcium channel Cav3. 2 in a mouse model of visceral hypersensitivity and in irritable bowel syndrome patients. Neurogastroenterol Motil. 2016;28(11):1632–1640. doi:10.1111/nmo.12860
    1. Ng QX, Soh AY, Loke W, et al. The role of inflammation in irritable bowel syndrome (IBS). J Inflamm Res. 2018;11:345. doi:10.2147/JIR.S174982
    1. Seyedmirzaee S, Hayatbakhsh MM, Ahmadi B, et al. Serum immune biomarkers in irritable bowel syndrome. Clin Res Hepatol Gastroenterol. 2016;40(5):631–637. doi:10.1016/j.clinre.2015.12.013
    1. Lee JY, Kim N, Park JH, et al. Expression of neurotrophic factors, tight junction proteins, and cytokines according to the irritable bowel syndrome subtype and sex. J Neurogastroenterol Motil. 2020;26(1):106. doi:10.5056/jnm19099
    1. Zhen Y, Chu C, Zhou S, Qi M, Shu R. Imbalance of tumor necrosis factor-α, interleukin-8 and interleukin-10 production evokes barrier dysfunction, severe abdominal symptoms and psychological disorders in patients with irritable bowel syndrome-associated diarrhea. Mol Med Report. 2015;12(4):5239–5245. doi:10.3892/mmr.2015.4079
    1. Farajollahi-Moghadam M, Sanjari-Moghaddam H, Hasemi MG, Sanatian Z, Talaei A, Akhondzadeh S. Efficacy and safety of pentoxifylline combination therapy in major depressive disorder: a randomized, double-blind, placebo-controlled clinical trial. Int Clin Psychopharmacol. 2021;36(3):140–146. doi:10.1097/YIC.0000000000000353
    1. Rai RR, Nijhawan S. Comparative evaluation of efficacy and safety of drotaverine versus mebeverine in irritable bowel syndrome: a randomized double-blind controlled study. Saudi J Gastroenterol. 2021;27(3):136. doi:10.4103/sjg.SJG_266_20
    1. Sekiguchi F, Kawabata A. T-type calcium channels: functional regulation and implication in pain signaling. J Pharmacol Sci. 2013;122(4):244–250. doi:10.1254/jphs.13R05CP
    1. Marger F, Gelot A, Alloui A, et al. T-type calcium channels contribute to colonic hypersensitivity in a rat model of irritable bowel syndrome. Proc Natl Acad Sci. 2011;108(27):11268–11273. doi:10.1073/pnas.1100869108
    1. Hamburg NM, Creager MA. Pathophysiology of intermittent claudication in peripheral artery disease. Circ J. 2017;81:281–289.
    1. McCarty MF, O’Keefe JH, Dinicolantonio JJ. Pentoxifylline for vascular health: a brief review of the literature. Open Heart. 2016;3(1):e000365. doi:10.1136/openhrt-2015-000365
    1. Kumar R, Prakash S, Chhabra S, et al. Association of pro-inflammatory cytokines, adipokines & oxidative stress with insulin resistance & non-alcoholic fatty liver disease. Indian J Med Res. 2012;136(2):229.
    1. Okunieff P, Augustine E, Hicks JE, et al. Pentoxifylline in the treatment of radiation-induced fibrosis. J Clin Oncol. 2004;22(11):2207–2213. doi:10.1200/JCO.2004.09.101
    1. Agharazii M, St-Louis R, Gautier-Bastien A, et al. Inflammatory cytokines and reactive oxygen species as mediators of chronic kidney disease-related vascular calcification. Am J Hypertens. 2015;28(6):746–755. doi:10.1093/ajh/hpu225
    1. Leporini C, Pisano A, Russo E, de Sarro G, Coppolino G, Bolignano D. Effect of pentoxifylline on renal outcomes in chronic kidney disease patients: a systematic review and meta-analysis. Pharmacol Res. 2016;107:315–332. doi:10.1016/j.phrs.2016.03.001
    1. Talley NJ, Kellow JE, Boyce P, Tennant C, Huskic S, Jones M. Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Dig Dis Sci. 2008;53(1):108–115.
    1. Peled A, Wald O, Burger J. Burger, development of novel CXCR4-based therapeutics. Expert Opin Investig Drugs. 2012;21(3):341–353. doi:10.1517/13543784.2012.656197
    1. Reme SE, Stahl D, Kennedy T, Jones R, Darnley S, Chalder T. Mediators of change in cognitive behaviour therapy and mebeverine for irritable bowel syndrome. Psychol Med. 2011;41(12):2669–2679. doi:10.1017/S0033291711000328
    1. El‑Haggar SM, Hegazy SK, Abd-Elsalam SM, Bahaa MM. “Pentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with mebeverine.”. Biomed Pharmacother. 2022;145:112399. doi:10.1016/j.biopha.2021.112399
    1. Talley NJ. Drug therapy options for patients with irritable bowel syndrome. Am J Manag Care. 2001;7(8 Suppl):S261–S267.
    1. Ward A, Clissold SP. Pentoxifylline. Drugs. 1987;34(1):50–97. doi:10.2165/00003495-198734010-00003
    1. Buchanan RA, Kinkel AW, Turner JL, et al. Ethosuximide dosage regimens. Clin Pharmacol Ther. 1976;19(2):143–147. doi:10.1002/cpt1976192143
    1. Husdan H, Rapoport A. Estimation of creatinine by the Jaffe reaction: a comparison of three methods. Clin Chem. 1968;14(3):222–238. doi:10.1093/clinchem/14.3.222
    1. Kahl C, Cleland JA. Visual analogue scale, numeric pain rating scale and the McGill pain questionnaire: an overview of psychometric properties. Phys Ther Rev. 2005;10(2):123–128. doi:10.1179/108331905X55776
    1. Mearin F, Ciriza C, Mínguez M, et al. Clinical Practice guideline: irritable bowel syndrome with constipation and functional constipation in the adult. Rev Esp Enferm Dig. 2016;108(6):332–363. doi:10.17235/reed.2016.4389/2016
    1. Donate-Correa J, Tagua VG, Ferri C, et al. Pentoxifylline for renal protection in diabetic kidney disease. A model of old drugs for new horizons. J Clin Med. 2019;8(3):287. doi:10.3390/jcm8030287
    1. Chen YM, Chiang W-C, Lin S-L, et al. Therapeutic efficacy of pentoxifylline on proteinuria and renal progression: an update. J Biomed Sci. 2017;24(1):1–15. doi:10.1186/s12929-017-0390-4
    1. Wen WX, Lee SY, Siang R, Koh RY. Repurposing pentoxifylline for the treatment of fibrosis: an overview. Adv Ther. 2017;34(6):1245–1269. doi:10.1007/s12325-017-0547-2
    1. Peterson TC, Peterson MR, Raoul JM. The effect of pentoxifylline and its metabolite-1 on inflammation and fibrosis in the TNBS model of colitis. Eur J Pharmacol. 2011;662(1–3):47–54. doi:10.1016/j.ejphar.2011.04.030
    1. Bashashati M, Moradi M, Sarosiek I. Interleukin-6 in irritable bowel syndrome: a systematic review and meta-analysis of IL-6 (-G174C) and circulating IL-6 levels. Cytokine. 2017;99:132–138. doi:10.1016/j.cyto.2017.08.017
    1. Jonefjäll B, Öhman L, Simrén M, Strid H. IBS-like symptoms in patients with ulcerative colitis in deep remission are associated with increased levels of serum cytokines and poor psychological well-being. Inflamm Bowel Dis. 2016;22(11):2630–2640. doi:10.1097/MIB.0000000000000921
    1. Chassaing B, Srinivasan G, Delgado MA, Young AN, Gewirtz AT, Vijay-Kumar M. Fecal lipocalin 2, a sensitive and broadly dynamic non-invasive biomarker for intestinal inflammation. PLoS One. 2012;7(9):e44328. doi:10.1371/journal.pone.0044328
    1. Sunil VR, Vayas KN, Cervelli JA, et al. Pentoxifylline attenuates nitrogen mustard-induced acute lung injury, oxidative stress and inflammation. Exp Mol Pathol. 2014;97(1):89–98. doi:10.1016/j.yexmp.2014.05.009
    1. Al-Gholam MA, Mansour FK, Abdel-Fattah NA, Nooh HZ. Effect of pentoxifylline on experimental-dextran sulphate sodium-induced colitis in rats. J Adv Med Med Res. 2014;4(10):2037–2057. doi:10.9734/BJMMR/2014/5108
    1. Vara EJ, Brokstad KA, Hausken T, Lied GA. Altered levels of cytokines in patients with irritable bowel syndrome are not correlated with fatigue. Int J Gen Med. 2018;11:285. doi:10.2147/IJGM.S166600
    1. Caviglia GP, Tucci A, Pellicano R, et al. “Clinical response and changes of cytokines and zonulin levels in patients with diarrhoea-predominant irritable bowel syndrome treated with bifidobacterium longum ES1 for 8 or 12 weeks: a preliminary report.”. J Clin Med. 2020;9(8):2353. doi:10.3390/jcm9082353
    1. Hustoft TN, Hausken T, Ystad SO, et al. Effects of varying dietary content of fermentable short‐chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome. Neurogastroenterol Motil. 2017;29(4):e12969. doi:10.1111/nmo.12969
    1. Karatay E, Utku Ö, Erdal H, et al. Pentoxifylline attenuates mucosal damage in an experimental model of rat colitis by modulating tissue biomarkers of inflammation, oxidative stress, and fibrosis. Turk J Med Sci. 2017;47(1):348–356. doi:10.3906/sag-1508-98
    1. González-Pacheco H, Amezcua-Guerra LM, Sandoval J, Arias-Mendoza A. Potential usefulness of pentoxifylline, a non-specific phosphodiesterase inhibitor with anti-inflammatory, anti-thrombotic, antioxidant, and anti-fibrogenic properties, in the treatment of SARS-CoV-2. Eur Rev Med Pharmacol Sci. 2020;24(14):7612–7614. doi:10.26355/eurrev_202007_22259
    1. Berg LK, Goll R, Fagerli E, et al. Intestinal inflammatory profile shows increase in a diversity of biomarkers in irritable bowel syndrome. Scand J Gastroenterol. 2020;55(5):537–542. doi:10.1080/00365521.2020.1754455
    1. Norlin AK, Walter S, Icenhour A, et al. Fatigue in irritable bowel syndrome is associated with plasma levels of TNF-α and mesocorticolimbic connectivity. Brain Behav Immun. 2021;92:211–222. doi:10.1016/j.bbi.2020.11.035
    1. El‑Haggar SM, Hegazy SKM, Abd‐Elsalam S, Bahaa MM. “Open‐label pilot study of ethosuximide as adjunctive therapy for relieving abdominal pain related to irritable bowel syndrome”. J Clin Pharm Ther. 2021. doi:10.1111/jcpt.13556
    1. Li B, Rui J, Ding X, Yang X. Exploring the multicomponent synergy mechanism of Banxia Xiexin decoction on irritable bowel syndrome by a systems pharmacology strategy. J Ethnopharmacol. 2019;233:158–168. doi:10.1016/j.jep.2018.12.033
    1. Murthy S, Cooper HS, Yoshitake H, Meyer C, Meyer CJ, Murthy NS. Combination therapy of pentoxifylline and TNFalpha monoclonal antibody in dextran sulphate-induced mouse colitis. Aliment Pharmacol Ther. 1999;13(2):251–260.
    1. Sørbye H, Svanes K. The role of blood flow in gastric mucosal defence, damage and healing. Dig Dis. 1994;12(5):305–317. doi:10.1159/000171465
    1. Warzecha Z, Dembiński A, Brzozowski T, et al. Histamine in stress ulcer prophylaxis in rats. J Physiol Pharmacol. 2001;52(3):407–421.
    1. Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol. 2005;77(5):598–625. doi:10.1189/jlb.1204697
    1. Lau D, Baldus S. Myeloperoxidase and its contributory role in inflammatory vascular disease. Pharmacol Ther. 2006;111(1):16–26. doi:10.1016/j.pharmthera.2005.06.023
    1. Pattison DI, Davies MJ. Reactions of myeloperoxidase-derived oxidants with biological substrates: gaining chemical insight into human inflammatory diseases. Curr Med Chem. 2006;13(27):3271–3290. doi:10.2174/092986706778773095
    1. Hansberry DR, Shah K, Agarwal P, Agarwal N. Fecal myeloperoxidase as a biomarker for inflammatory bowel disease. Cureus. 2017;9(1):e1004. doi:10.7759/cureus.1004
    1. Majeed M, Nagabhushanam K, Arumugam S, Majeed S, Ali F. Bacillus coagulans MTCC 5856 for the management of major depression with irritable bowel syndrome: a randomised, double-blind, placebo controlled, multi-centre, pilot clinical study. Food Nutr Res. 2018;62. doi:10.29219/fnr.v62.1218
    1. Li H, Tan G, Tong L, et al. Pentoxifylline inhibits pulmonary inflammation induced by infrarenal aorticcross-clamping dependent of adenosine receptor A2A. Am J Transl Res. 2016;8(5):2210.
    1. Kumar S, Roat R, Agrawal S, Jayant K, Mavuduru RS, Kumar S. Combination therapy of tadalafil and pentoxifylline in severe erectile dysfunction; A prospective randomized trial. Pol J Surg. 2015;87(8):377–383. doi:10.1515/pjs-2015-0075
    1. Law YX, Tai BC, Tan YQ, Lata RN, Lee KC. A small group randomized double-blind placebo-controlled study to evaluate the efficacy of daily pentoxifylline in the management of patients with erectile dysfunction with suboptimal treatment response to sildenafil. Sex Med. 2020;8(1):14–20. doi:10.1016/j.esxm.2019.08.012

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir